Rate of complete metabolic responses to immune checkpoint inhibitors in extremely heavily pre-treated patients with classical Hodgkin’s lymphoma and immunoepigenetic priming

Authors :: Jennifer E Amengual
Owen A. O'Connor
Changchun Deng
Emily Lichtenstein
Michael J. Smith
Karen Khan
Ahmed Sawas
Heather Dials
Lorenzo Falchi
Donald Steven Colbourn
Source :: Journal of Clinical Oncology. 34:e19012-e19012
Publication Year :: 2016
Publisher :: American Society of Clinical Oncology (ASCO), 2016.
Abstract: e19012Background: Options for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) after failure of brentuximab vedotin (Bv) and ASCT are limited. cHL is associated with genetically determine...

Full Text Access

Tools